Active Recombinant Human SMARCA4

• Cat.No.: SMARCA4-1019H

Specification

• Cat. No.: SMARCA4-1019H
• Description: The wild type human brahma-related gene 1 (Brg1) encodes a protein of 1,647 amino acids that contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription regulation. BRG1 is an essential component of the SWI/SNF chromatin remodeling complexes and implicated in multiple functions through its interaction with different proteins, including the tumor suppressor protein pRb, serine-threonine kinase LKB1, and other transcription factors. Although Brg1 involves in chromatin remodeling as complexes with other SWI/SNF proteins, purified BRG1 itself is capable of remodeling mononucleosomes and nucleosomal arrays in vitro. Mutations of Brg1 have been found in multiple tumor cell lines. The wild type human BRG1 was expressed in baculovirus system and purified by an affinity column in combination with FPLC chromatography. Purified protein is greater than 95% homogeneous and contains no detectable proteases, DNase, and RNase activity.
• Source: Sf9 insect cells.
• Form: Liquid. Supplied in 20 mM Tris-HCl pH 8.0, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT, 20% glycerol.
• Purity: > 95% by SDS-PAGE.
• Activity: 50-100 ng are required for in vitro nucleosome remodeling assay and 100 ng are required for a protein-protein interaction assay.
• Application: Recombinant BRG1 can be used 1) for protein-protein interaction assay 2) for in vitro transcription assay 3) for in vitro nucleosome remodeling assay and 4) for cell growth assay.
• Usage: For in vitro use only.
• Storage: Quality guaranteed for 12 months store at - 80°C. Avoid freeze / thaw cycles.
• Tag: Non

Gene Information

• Gene Name: SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Homo sapiens ]
• Synonyms: SMARCA4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; BRG1; SNF2; SWI2; BAF190; SNF2L4; SNF2LB; hSNF2b; FLJ39786; SNF2-BETA; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4; SNF2-like 4; nuclear protein GRB1; brahma protein-like 1; BRM/SWI2-related gene 1; homeotic gene regulator; sucrose nonfermenting-like 4; ATP-dependent helicase SMARCA4; mitotic growth and transcription activator; global transcription activator homologous sequence; SNF2B; Probable global transcription activator SNF2L4; EC 3.6.1.-; BRG-1 protein; nuclear protein GRB1
• Gene ID: 6597
• mRNA Refseq: NM_001128844
• Protein Refseq: NP_001122316
• MIM: 603254
• UniProt ID: P51532
• Chromosome Location: 19p13.3
• Function: ATP binding; DNA binding; DNA-dependent ATPase activity; helicase activity; histone acetyl-lysine binding; hydrolase activity; hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides; identical protein binding; nucleotide binding; p53 binding; protein N-terminus binding; transcription activator activity

Reviews

02/18/2023

The SMARCA4 protein offers exceptional quality that meets the rigorous demands of experimental research.

11/01/2018

It exhibits exceptional performance in ELISA assays, making it an excellent choice for researchers studying angiopoietins, angiogenesis, or vascular biology.

10/30/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Can epigenetic therapies target SMARCA4 alterations?

Epigenetic therapies that modulate gene expression could indirectly affect SMARCA4-altered cancers, though specific targeting remains a challenge.

Are there diagnostic tests for SMARCA4 mutations?

Yes, there are genetic tests available to identify SMARCA4 mutations in tumors, aiding in prognosis and treatment decisions.

Are there ongoing clinical trials focusing on SMARCA4 alterations?

Yes, there are clinical trials exploring new treatment strategies for SMARCA4-altered cancers, aiming to improve patient outcomes.

Is SMARCA4 solely associated with cancer?

No, SMARCA4's functions extend beyond cancer and have implications in various biological processes, including development and differentiation.

How can SMARCA4 mutations influence patient prognosis?

Patients with SMARCA4 mutations in their tumors often face a poorer prognosis, which necessitates tailored treatment approaches.